Literature DB >> 26232325

CXCL12-CXCR4/CXCR7 axis contributes to cell motilities of oral squamous cell carcinoma.

Na Chen1, Xiao Jiang1, Juan Wang1, Tong Wu1, Bin Cheng2, Juan Xia3.   

Abstract

The chemokine CXCL12 and its receptors CXCR4 and CXCR7 might play important roles in the occurrence and development of oral squamous cell carcinoma (OSCC). While CXCR4 expression is associated to initiation and progression of OSCC, the role of CXCR7, the recently founded second CXCL12 receptor, has not yet been elucidated in OSCC. In this study, CXCR4 and CXCR7 expressions were evaluated using western blot and quantitative RT-PCR in OSCC cells. AMD3100 (CXCR4 antagonist) was used to inhibit the activation of CXCR4. In contrast to CXCR4, effective CXCR7 small interfering RNA (siRNA) segments were used to silence CXCR7 in OSCC cells. The biological effects of CXCL12-CXCR4/CXCR7 axis on OSCC cell lines were studied by CCK-8 and transwell assay. As determined by RT-PCR and Western blot, CXCR7 expression was significantly downregulated after siRNA transfection in OSCC cells, and thus significantly promoted OSCC cell migration and invasion in vitro. The relative roles of the two CXCL12 receptors were further assessed by CXCR7 knockdown or deactivate CXCR4 receptor alone, or in combination, in the OSCC cells. In vitro functional analyses indicated that, in response to their common ligand (CXCL12), both receptors induced inhibition of proliferation and migration in OSCC cells in a dose-dependent manner. Exogenous CXCL12 could promote cell migration and invasion. In conclusion, our results indicated that CXCL12 which combined its receptor CXCR4 and CXCR7 together could promote cell motilities of OSCC.

Entities:  

Keywords:  CXCL12; CXCR4; CXCR7; Oral squamous cell carcinoma

Mesh:

Substances:

Year:  2015        PMID: 26232325     DOI: 10.1007/s13277-015-3803-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  31 in total

Review 1.  An infernal trio: the chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology.

Authors:  Kirsten Hattermann; Rolf Mentlein
Journal:  Ann Anat       Date:  2012-12-08       Impact factor: 2.698

2.  High expression of CXCR4 and CXCR7 predicts poor survival in gallbladder cancer.

Authors:  X Yao; L Zhou; S Han; Y Chen
Journal:  J Int Med Res       Date:  2011       Impact factor: 1.671

3.  Expressions of CXCR7/ligands may be involved in oral carcinogenesis.

Authors:  Juan Xia; Juan Wang; Na Chen; Yaohui Dai; Yun Hong; Xiaobing Chen; Bin Cheng
Journal:  J Mol Histol       Date:  2011-03-26       Impact factor: 2.611

4.  Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer.

Authors:  H Imai; N Sunaga; Y Shimizu; S Kakegawa; K Shimizu; T Sano; T Ishizuka; T Oyama; R Saito; J D Minna; M Mori
Journal:  Int J Immunopathol Pharmacol       Date:  2010 Jan-Mar       Impact factor: 3.219

5.  Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases.

Authors:  Daisuke Uchida; Tomitaro Onoue; Nobuyuki Kuribayashi; Yoshifumi Tomizuka; Tetsuya Tamatani; Hirokazu Nagai; Youji Miyamoto
Journal:  Eur J Cancer       Date:  2010-10-19       Impact factor: 9.162

6.  CXCR4 expression mediates glioma cell invasiveness.

Authors:  M Ehtesham; J A Winston; P Kabos; R C Thompson
Journal:  Oncogene       Date:  2006-05-04       Impact factor: 9.867

7.  Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma.

Authors:  Florian Gebauer; Michael Tachezy; Katharina Effenberger; Katharina von Loga; Hilke Zander; Alexander Marx; Jussuf T Kaifi; Guido Sauter; Jakob R Izbicki; Maximilian Bockhorn
Journal:  J Surg Oncol       Date:  2011-04-25       Impact factor: 3.454

8.  CXCL12 enhances human neural progenitor cell survival through a CXCR7- and CXCR4-mediated endocytotic signaling pathway.

Authors:  Bing Zhu; Dongsheng Xu; Xiaobei Deng; Qiang Chen; Yunlong Huang; Hui Peng; Yuju Li; Beibei Jia; Wallace B Thoreson; Wenjun Ding; Jianqing Ding; Lixia Zhao; Yi Wang; Kristin Leland Wavrin; Shumin Duan; Jialin Zheng
Journal:  Stem Cells       Date:  2012-11       Impact factor: 6.277

9.  Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells.

Authors:  Antoine Boudot; Gwenneg Kerdivel; Denis Habauzit; Jerome Eeckhoute; François Le Dily; Gilles Flouriot; Michel Samson; Farzad Pakdel
Journal:  PLoS One       Date:  2011-06-10       Impact factor: 3.240

10.  A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development.

Authors:  Jennifer M Burns; Bretton C Summers; Yu Wang; Anita Melikian; Rob Berahovich; Zhenhua Miao; Mark E T Penfold; Mary Jean Sunshine; Dan R Littman; Calvin J Kuo; Kevin Wei; Brian E McMaster; Kim Wright; Maureen C Howard; Thomas J Schall
Journal:  J Exp Med       Date:  2006-08-28       Impact factor: 14.307

View more
  5 in total

1.  miRNA-101 acts as a tumor suppressor in oral squamous cell carcinoma by targeting CX chemokine receptor 7.

Authors:  Yuan Hui; Yu Li; Yan Jing; Jian-Q Feng; Yin Ding
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

Review 2.  The cytokine network in acute myeloid leukemia.

Authors:  Michela Luciano; Peter W Krenn; Jutta Horejs-Hoeck
Journal:  Front Immunol       Date:  2022-09-28       Impact factor: 8.786

3.  CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma.

Authors:  Thomas A Werner; Christina M Forster; Levent Dizdar; Pablo E Verde; Katharina Raba; Matthias Schott; Wolfram T Knoefel; Andreas Krieg
Journal:  Br J Cancer       Date:  2017-11-07       Impact factor: 7.640

4.  CXCR4/CXCR7/CXCL12-Axis in Follicular Thyroid Carcinoma.

Authors:  Thomas Artur Werner; Christina Maria Forster; Levent Dizdar; Pablo Emilio Verde; Katharina Raba; Matthias Schott; Wolfram Trudo Knoefel; Andreas Krieg
Journal:  J Cancer       Date:  2018-02-27       Impact factor: 4.207

5.  Bioinformatics analysis reveals that ANXA1 and SPINK5 are novel tumor suppressor genes in patients with oral squamous cell carcinoma.

Authors:  Hua-Tao Wu; Wen-Tian Chen; Wen-Jia Chen; Chun-Lan Li; Jing Liu
Journal:  Transl Cancer Res       Date:  2021-04       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.